Made Scientific, a cell therapy contract development and manufacturing organization, cut the ribbon Aug. 13 to officially open its 60,000 square-foot GMP manufacturing facility and headquarters.
The event underscores New Jersey’s role in the expanding field of advanced biomanufacturing and cell and gene therapy innovation. The state is home to eight of the top 10 global biopharmaceutical companies, eight of the top 10 R&D companies, and more than 5,600 life-sciences establishments, according to business advocacy group Choose New Jersey.
“We are very pleased that Made Scientific, a leading cell therapy CDMO, has made the decision to locate its new headquarters and GMP manufacturing facility here in Plainsboro. It reinforces the strength of our town and workforce that locating in Plainsboro is a positive decision for Made Scientific and other pharma and biotech companies,” said Mayor Edmund Yates. “We know that Made Scientific will have a transformative impact in the development and manufacturing of breakthrough medicines for patients worldwide.”
Yates was joined by representatives from the offices of Sen. Andy Kim and Rep. Bonnie Watson Coleman, along with other federal, state, and local partners.
The opening marks the completion of a $12 million initial investment in facility upgrades, equipment, and business system digitization, strengthening Made Scientific’s position in the rapidly growing cell therapy sector and commitment to building long-term manufacturing capacity to support the next generation of cell therapies globally. A second phase of expansion has been announced, and the company is expected to grow its workforce with more than 100 additional people.
According to the HealthCare Institute of New Jersey, life sciences-supported positions account for 369,000 direct and indirect sector jobs, or 8.1% of the state’s total workforce.
“Today is more than a ribbon cutting. It is a clear signal of our commitment to this incredible industry and to this region,” said Syed T. Husain, chairman and CEO of Made Scientific. “This facility is a testament to our dedication to supporting the next generation of cell therapy innovators for clinical-to-commercial manufacturing, all under one roof.”
Guests at the event explored purpose-built process development labs and GMP cleanroom suites designed to support scalable GMP manufacturing for both autologous and allogeneic therapies. The facility includes five ISO 7 / Grade B cleanrooms, in-house quality control labs, and dedicated process and analytical development capabilities. It also incorporates advanced digital infrastructure.
The event also highlighted Made Scientific’s recent announcement of an additional 12,000 square-foot build-out of GMP manufacturing cleanroom space, which will meet U.S. FDA and EU Annex 1 compliance standards and include high-throughput and automated manufacturing technologies. Once fully operational, the expansion will increase capacity by up to 2,000 additional batches per year to support late-phase and commercial programs.
Made Scientific was rebranded from BioCentriq in March.
